South Dakota Investment Council lowered its stake in shares of Sanofi (NYSE:SNY) by 40.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,647 shares of the company’s stock after selling 9,200 shares during the period. South Dakota Investment Council’s holdings in Sanofi were worth $654,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in the company. Founders Financial Securities LLC acquired a new stake in Sanofi during the 2nd quarter valued at $907,000. Goodwin Daniel L bought a new position in Sanofi during the 2nd quarter valued at $239,000. Wellington Management Group LLP bought a new position in Sanofi during the 1st quarter valued at $2,252,000. Stifel Financial Corp boosted its stake in Sanofi by 8.6% during the 1st quarter. Stifel Financial Corp now owns 317,185 shares of the company’s stock valued at $14,362,000 after acquiring an additional 25,009 shares during the last quarter. Finally, Bluestein R H & Co. boosted its stake in Sanofi by 7.5% during the 1st quarter. Bluestein R H & Co. now owns 21,500 shares of the company’s stock valued at $973,000 after acquiring an additional 1,500 shares during the last quarter. 9.33% of the stock is owned by institutional investors.
Sanofi (NYSE SNY) opened at 50.34 on Friday. Sanofi has a 52 week low of $36.81 and a 52 week high of $50.65. The firm has a market cap of $126.43 billion, a PE ratio of 11.74 and a beta of 0.88. The stock has a 50 day moving average of $48.38 and a 200 day moving average of $47.45.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. Sanofi’s revenue for the quarter was down 2.3% on a year-over-year basis. Analysts anticipate that Sanofi will post $3.33 EPS for the current year.
Several analysts recently weighed in on the stock. Argus reiterated a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research report on Friday, September 1st. BidaskClub upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a research report on Friday, June 2nd. HSBC Holdings plc raised shares of Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Finally, Cowen and Company reissued a “market perform” rating and set a $52.00 target price (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. Sanofi currently has a consensus rating of “Hold” and a consensus price target of $54.00.
ILLEGAL ACTIVITY NOTICE: This story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://ledgergazette.com/2017/09/23/sanofi-sny-shares-sold-by-south-dakota-investment-council.html.
In other news, major shareholder Sanofi acquired 105,820 shares of the firm’s stock in a transaction dated Thursday, August 24th. The stock was purchased at an average price of $482.04 per share, for a total transaction of $51,009,472.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.00% of the company’s stock.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.